Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 600 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC September 2, 2022 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 Answers to Your Questions About the COVID-19 Vaccine March 4, 2021 Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... December 17, 2020 Load more HOT NEWS How Genomic Testing Brought Me a Sense of Control During Metastatic... Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative... Cancer in My Community: Addressing Regional Cancer Disparities in Peru Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical...
